First time first dynamic

Dr. Yonggang Chen has been appointed as the company’s senior vice president and chief technology officer, taking charge of the Haoyuan Chemexpress CDMO business.

Page View:583 Back

Recently, Haoyuan Chemexpress hired Dr. Chen Yonggang as the company’s senior vice president and chief technology officer (CTO). He has taken the responsibility of the company’s CDMO business management to promote, enhance the company’s CDMO service capabilities and strengthen the company’s core Competitiveness.

Dr. Chen Yonggang, born in 1972, graduated from Lanzhou University with a Master’s degree in organic chemistry and a Ph.D. in organic chemistry from Brandeis University, the United States (2003). He has done his post-doctoral research at Eric N. Jacobsen laboratory, Harvard University (2003-2005). Since 2005, he has been working at Merck & Co., New Jersey, USA, as the principal scientist, engaged in small molecule drug synthesis process, high-throughput experiment/catalytic screening, and managed outsourcing of development and production of active pharmaceutical ingredients. During his tenure, he has won 14 internal awards.  Including the Merck Green Chemistry Award, the Merck Chairman Award, the R&D New Tools and Method Award, and the Process R&D Publication Award. He has also won the 2019 U.S. Environmental Protection Agency (EPA) Green Chemistry Challenge Award. He has published 28 papers and applied for 11 invention patents.

Dr. Chen Yonggang has rich industry experience in drug synthesis process development and management. In Haoyuan Chemexpress, He will be responsible for the global strategic development and operation management of the CDMO business. He will lead the R&D and production team to improve the process route optimization and strengthen the technology platform to expand the CDMO pipeline business. Develop capabilities to accelerate the up-gradation of production capacity. Provide efficient, high-quality, and optimized solutions to promote and launch new drugs for global pharmaceutical and biomedical R&D companies.

Recent News